A group of researchers based at the Papa Giovanni XXIII hospital in Italy have submitted evidence to suggest that individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may adequately benefit from a single dose of mRNA vaccine, rather than requiring the current two-vaccine regimen.